Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium

Phase 1 Completed 33 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab

RandomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of urothelial cancer. PURPOSE: This randomized phase I trial is studying how well low-dose interferon alfa works in treating patients with cancer of the urothelium.

Timeline

Start: 2003-12
Primary completion: 2015-01
Completion: 2015-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	interferon alfa-2b	Protein / enzyme biologic	—	Subcutaneous

Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium

Summary

Timeline

Drugs

Indications